Moderna announces new development programs ahead of 3rd annual vaccines day

Mrna-1230 is a combination respiratory vaccine candidate against sars-cov-2 virus, influenza virus and respiratory syncytial virus (rsv) mrna-1287 is a vaccine candidate against the four endemic human coronaviruses (hcov-229e, -nl63, -oc43 and -hku1) cambridge, ma / accesswire / march 22, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that it is expanding its mrna pipeline with two new development programs. this announcement reflects the company's commitment to expanding its portfolio by building on moderna's experience with spikevax®, its covid-19 vaccine.
MRNA Ratings Summary
MRNA Quant Ranking